603707 健友股份
已收盘 11-06 15:00:00
资讯
新帖
简况
健友股份（603707）11月6日主力资金净卖出1.01万元
证券之星 · 11-07 08:36
健友股份（603707）11月6日主力资金净卖出1.01万元
健友股份（603707）11月5日主力资金净买入2221.92万元
证券之星 · 11-06 08:15
健友股份（603707）11月5日主力资金净买入2221.92万元
股市必读：健友股份（603707）11月2日董秘有最新回复
证券之星 · 11-03
股市必读：健友股份（603707）11月2日董秘有最新回复
健友股份：公司第三季度营业收入同比增长14.13%
证券之星 · 11-02
健友股份：公司第三季度营业收入同比增长14.13%
健友股份（603707）2026年三季报简析：增收不增利
证券之星 · 11-01
健友股份（603707）2026年三季报简析：增收不增利
健友股份（603707）披露关于关联交易合同主体变更的公告，10月30日股价上涨1.13%
证券之星 · 10-30
健友股份（603707）披露关于关联交易合同主体变更的公告，10月30日股价上涨1.13%
健友股份：阿达木单抗、利拉鲁肽、门冬胰岛素等多个产品已获美国FDA批准
证券之星 · 10-27
健友股份：阿达木单抗、利拉鲁肽、门冬胰岛素等多个产品已获美国FDA批准
股市必读：健友股份新发布《健友股份关于子公司产品甲磺酸艾立布林注射液获得美国FDA批准的公告》
证券之星 · 10-22
股市必读：健友股份新发布《健友股份关于子公司产品甲磺酸艾立布林注射液获得美国FDA批准的公告》
健友股份：累计已取得超过100项海外批件
证券之星 · 10-21
健友股份：累计已取得超过100项海外批件
健友股份(603707.SH)子公司产品甲磺酸艾立布林注射液获得美国FDA批准
智通财经 · 10-20
健友股份(603707.SH)子公司产品甲磺酸艾立布林注射液获得美国FDA批准
股市必读：健友股份（603707）10月14日董秘有最新回复
证券之星 · 10-15
股市必读：健友股份（603707）10月14日董秘有最新回复
股市必读：健友股份新发布《健友股份关于子公司产品阿达木单抗注射液获得美国FDA批准的公告》
证券之星 · 10-08
股市必读：健友股份新发布《健友股份关于子公司产品阿达木单抗注射液获得美国FDA批准的公告》
健友股份（603707）披露子公司阿达木单抗注射液获美国FDA批准，9月29日股价下跌0.25%
证券之星 · 09-29
健友股份（603707）披露子公司阿达木单抗注射液获美国FDA批准，9月29日股价下跌0.25%
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
央广财经 · 09-28
沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花
健友股份(603707.SH)子公司产品维生素B1注射液获得美国FDA批准
智通财经 · 09-28
健友股份(603707.SH)子公司产品维生素B1注射液获得美国FDA批准
股市必读：健友股份新发布《健友股份关于全资子公司参与认购私募基金份额的公告》
证券之星 · 09-28
股市必读：健友股份新发布《健友股份关于全资子公司参与认购私募基金份额的公告》
健友股份（603707）披露全资子公司参与认购私募基金份额公告，9月24日股价下跌2.65%
证券之星 · 09-24
健友股份（603707）披露全资子公司参与认购私募基金份额公告，9月24日股价下跌2.65%
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告》
证券之星 · 09-24
股市必读：健友股份新发布《健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告》
健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件
同花顺 · 09-22
健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件
股市必读：健友股份（603707）9月15日董秘有最新回复
证券之星 · 09-16
股市必读：健友股份（603707）9月15日董秘有最新回复
加载更多
公司概况
公司名称：
南京健友生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-07-19
主营业务：
南京健友生化制药股份有限公司的主营业务是药物的研发、规模化生产、全球商业化销售并提供一站式无菌注射剂CDMO服务。公司的主要产品是无菌注射剂业务、肝素原料药业务、CDMO业务、生物药创新业务。
发行价格：
7.21
{"stockData":{"symbol":"603707","market":"SH","secType":"STK","nameCN":"健友股份","latestPrice":8.88,"timestamp":1793948400000,"preClose":8.71,"halted":0,"volume":28279141,"delay":0,"changeRate":0.0195,"floatShares":1616000000,"shares":1616000000,"eps":0.2632,"marketStatus":"已收盘","change":0.17,"latestTime":"11-06 15:00:00","open":8.55,"high":9.03,"low":8.53,"amount":250000000,"amplitude":0.0574,"askPrice":8.88,"askSize":331,"bidPrice":8.87,"bidSize":104,"shortable":0,"etf":0,"ttmEps":0.2632,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":8.71,"symbolType":"stock","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":9.58,"lowLimit":7.84,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1615651020,"isCdr":false,"pbRate":2.05,"roa":"--","peRate":33.738602,"roe":"3.92%","epsLYR":0.36,"committee":-0.014844,"marketValue":14347000000,"turnoverRate":0.0175,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-09。","floatMarketCap":14347000000},"requestUrl":"/m/hq/s/603707","defaultTab":"news","newsList":[{"id":"2681981818","title":"健友股份（603707）11月6日主力资金净卖出1.01万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681981818","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681981818?lang=zh_cn&edition=full","pubTime":"2026-11-07 08:36","pubTimestamp":1794011817,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月6日收盘，健友股份报收于8.88元，上涨1.95%，换手率1.75%，成交量28.28万手，成交额2.5亿元。融券方面，融券卖出1700.0股，融券偿还8100.0股，融券余量26.72万股，融券余额237.27万元。健友股份主营业务：是一家集药品研发、生产、销售为一体的制药企业,积极布局化学药、生物药领域,建立涵盖心血管、神经类、麻醉剂、抗肿瘤制剂、手术辅助类及其他高附加值无菌注射剂等丰富的产品管线,是全球市场多品种注射剂的供应商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110700009939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681881253","title":"健友股份（603707）11月5日主力资金净买入2221.92万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681881253","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681881253?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:15","pubTimestamp":1793924123,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月5日收盘，健友股份报收于8.71元，上涨7.53%，换手率2.15%，成交量34.68万手，成交额2.96亿元。11月5日的资金流向数据方面，主力资金净流入2221.92万元，占总成交额7.51%，游资资金净流出4103.46万元，占总成交额13.88%，散户资金净流入1881.54万元，占总成交额6.36%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600008275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680764737","title":"股市必读：健友股份（603707）11月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2680764737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680764737?lang=zh_cn&edition=full","pubTime":"2026-11-03 01:50","pubTimestamp":1793641848,"startTime":"0","endTime":"0","summary":"截至2026年11月2日收盘，健友股份报收于8.17元，上涨1.11%，换手率0.96%，成交量15.56万手，成交额1.26亿元。董秘最新回复投资者： 三季度单季营收增长了14%多，算是有点起色了。公司第三季度公司营业收入同比增长14.13%，体现了主营业务的经营韧性。当日关注点交易信息汇总：11月2日主力资金净流出570.26万元，占总成交额4.52%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300003496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","603707","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680173413","title":"健友股份：公司第三季度营业收入同比增长14.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680173413","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680173413?lang=zh_cn&edition=full","pubTime":"2026-11-02 16:33","pubTimestamp":1793608404,"startTime":"0","endTime":"0","summary":"证券之星消息，健友股份11月02日在投资者关系平台上答复投资者关心的问题。投资者提问：三季度单季营收增长了14%多，算是有点起色了。公司第三季度公司营业收入同比增长14.13%，体现了主营业务的经营韧性。后续，公司将继续推动已获批产品的市场转化，但单季度收入可能受订单、发货及市场节奏等因素影响，具体经营情况请以后续定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200022852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680274079","title":"健友股份（603707）2026年三季报简析：增收不增利","url":"https://stock-news.laohu8.com/highlight/detail?id=2680274079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680274079?lang=zh_cn&edition=full","pubTime":"2026-11-01 06:20","pubTimestamp":1793485217,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期健友股份发布2026年三季报。根据财报显示，健友股份增收不增利。截至本报告期末，公司营业总收入30.06亿元，同比上升2.74%，归母净利润2.73亿元，同比下降36.4%。按单季度数据看，第三季度营业总收入10.8亿元，同比上升14.13%，第三季度归母净利润8559.69万元，同比下降40.23%。本次财报公布的各项数据指标表现一般。去年的净利率为14.57%，算上全部成本后，公司产品或服务的附加值高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110100001190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0046","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679243432","title":"健友股份（603707）披露关于关联交易合同主体变更的公告，10月30日股价上涨1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679243432","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679243432?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:59","pubTimestamp":1793372362,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，健友股份报收于8.08元，较前一交易日上涨1.13%，最新总市值为130.54亿元。近日，南京健友生化制药股份有限公司发布《关于关联交易合同主体变更的公告》。公告显示，公司全资子公司香港健友及控股子公司Meitheal与Xentria签署《许可协议》，获得XTMAB在许可区域的独占许可。现因内部架构调整，拟将合同原被许可方代表由香港健友变更为其全资子公司Emerge，在原协议基础上签订补充协议，仅变更签约主体，其他内容无实质变化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000058171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678212556","title":"健友股份：阿达木单抗、利拉鲁肽、门冬胰岛素等多个产品已获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2678212556","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678212556?lang=zh_cn&edition=full","pubTime":"2026-10-27 15:33","pubTimestamp":1793086427,"startTime":"0","endTime":"0","summary":"公司关注到近期美国FDA持续优化生物类似药审评审批政策、简化部分临床研究要求的监管动向，若相关趋势落地实施，有利于缩短生物类似药的研发与上市周期，对行业发展具有积极意义。公司已建立覆盖胰岛素、单抗等品类的生物类似药产品矩阵，阿达木单抗、利拉鲁肽、门冬胰岛素等多个产品已获美国FDA批准，另有多个在研品种正有序推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700024239.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0046","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677606310","title":"股市必读：健友股份新发布《健友股份关于子公司产品甲磺酸艾立布林注射液获得美国FDA批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2677606310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677606310?lang=zh_cn&edition=full","pubTime":"2026-10-22 01:21","pubTimestamp":1792603269,"startTime":"0","endTime":"0","summary":"公司公告汇总：健友股份子公司甲磺酸艾立布林注射液获美国FDA批准，ANDA号218930，适应症为转移性乳腺癌及不可切除或转移性脂肪肉瘤。董秘： 尊敬的投资者您好，近期公司硫酸阿米卡星注射液增加南京生产场地，甲磺酸艾立布林注射液、维生素B1注射液、阿达木单抗注射液相继获得美国FDA批准，公司累计已取得超过100项海外批件，注册申报与产业化能力持续得到国际规范市场验证。后续产品获批及销售情况请以公司公告及定期报告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200001181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677625948","title":"健友股份：累计已取得超过100项海外批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2677625948","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677625948?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:33","pubTimestamp":1792568015,"startTime":"0","endTime":"0","summary":"投资者提问：公司9-10月接连拿了好几个FDA批件，这个速度还是可以的，公司在美国的注册生产能力现在在国内属于什么水平？健友股份回复：尊敬的投资者您好，近期公司硫酸阿米卡星注射液增加南京生产场地，甲磺酸艾立布林注射液、维生素B1注射液、阿达木单抗注射液相继获得美国FDA批准，公司累计已取得超过100项海外批件，注册申报与产业化能力持续得到国际规范市场验证。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100021556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0186","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676668617","title":"健友股份(603707.SH)子公司产品甲磺酸艾立布林注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2676668617","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676668617?lang=zh_cn&edition=full","pubTime":"2026-10-20 15:46","pubTimestamp":1792482360,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司子公司健进制药有限公司于近日收到美国食品药品监督管理局(简称“美国FDA”)签发的甲磺酸艾立布林注射液(1mg/2mL)的ANDA批准通知。该药品适用于既往已接受过至少两种化疗方案治疗的转移性乳腺癌患者，以及既往接受过含蒽环类药物治疗方案的不可切除或转移性脂肪肉瘤患者。新批准产品进一步丰富了公司国际化的产品管线，强化公司国际市场布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1509346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0046","LABU","BK0186","BK4585","BK4588","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675216513","title":"股市必读：健友股份（603707）10月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2675216513","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675216513?lang=zh_cn&edition=full","pubTime":"2026-10-15 02:19","pubTimestamp":1792001948,"startTime":"0","endTime":"0","summary":"截至2026年10月14日收盘，健友股份报收于8.0元，上涨0.0%，换手率0.41%，成交量6.58万手，成交额5263.76万元。董秘最新回复投资者： 看到公司阿达木单抗新规格在美国获批了，公告里说跟修美乐可互换具体是什么意思？公司子公司Emerge Bioscience Pte. Ltd. 阿达木单抗注射液近期获美国FDA批准。该产品后续商业化落地节奏，将结合美国市场环境、渠道布局情况稳步推进。目前该产品尚未在美国开展上市销售，短期不会对公司经营业绩构成重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500001824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","603707","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673012652","title":"股市必读：健友股份新发布《健友股份关于子公司产品阿达木单抗注射液获得美国FDA批准的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673012652","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673012652?lang=zh_cn&edition=full","pubTime":"2026-10-08 01:59","pubTimestamp":1791395947,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，健友股份报收于8.19元，上涨3.8%，换手率1.11%，成交量18.01万手，成交额1.46亿元。当日关注点交易信息汇总：9月30日主力资金净流入582.71万元，占总成交额3.98%。公司公告汇总：健友股份子公司阿达木单抗注射液获美国FDA批准，获批规格与修美乐注射液具有可互换性，BLA号为761216。该产品为生物类似药，商品名为YUSIMRY，此前由Coherus BioSciences持有，本次获批规格与已获批修美乐注射液具有可互换性。公司为此项目累计投入研发费用约13,866.67万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0186","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671487742","title":"健友股份（603707）披露子公司阿达木单抗注射液获美国FDA批准，9月29日股价下跌0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2671487742","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671487742?lang=zh_cn&edition=full","pubTime":"2026-09-29 22:36","pubTimestamp":1790692580,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘，健友股份报收于7.89元，较前一交易日下跌0.25%，最新总市值为127.47亿元。该股当日开盘7.95元，最高7.98元，最低7.81元，成交额达6336.19万元，换手率为0.5%。近日，健友股份发布关于子公司产品阿达木单抗注射液获得美国FDA批准的公告。公告显示，公司全资子公司Emerge Bioscience Pte. Ltd.收到美国FDA批件，其申报的阿达木单抗注射液获得批准，BLA号为761216。公司为此项目累计投入研发费用约13,866.67万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900040654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0186","603707","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670875258","title":"沪市公司晚间利好密集释放 回购增持、重组与经营突破多点开花","url":"https://stock-news.laohu8.com/highlight/detail?id=2670875258","media":"央广财经","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670875258?lang=zh_cn&edition=full","pubTime":"2026-09-28 21:22","pubTimestamp":1790601766,"startTime":"0","endTime":"0","summary":"央广网北京9月28日消息（记者牛谷月）9月28日晚间，沪市（含科创板）超20家上市公司集中发布多项利好公告，内容涵盖股份回购增持、资产重组、药品获批、重大经营合同落地等。多家企业以真金白银彰显对自身长期发展的信心，同时披露业务拓展新进展，向市场传递积极信号。回购增持成为本次晚间公告的重头戏，共有12家公司发布相关方案或实施进展。其中，两家公司抛出全新回购预案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609283885425388.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609283885425388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0201","BK0184","BK0196","LU1720050803.USD","688032","LU1969619763.USD","BK0175","BK0187","603707","688349","BK0067","BK0097","600720","LU2097828714.EUR","BK0020","LU2097828805.USD","601126","BK0010","BK0183","LU0456846285.SGD","SGXZ49509284.SGD","603195","601607","BK0209","BK0231","603296","BK0015","LU2580892862.HKD","BK0012","605303","LU2148510915.USD","LU0456827905.SGD","600690","BK0028","BK0259","LU1794554557.SGD","SGXZ81163826.USD","BK0235","688111","BK0044","BK0026","IE0005HP3H50.USD","BK0000","LU2097828474.EUR","688251","603310","LU1580142542.USD","601117","BK0277","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670280512","title":"健友股份(603707.SH)子公司产品维生素B1注射液获得美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2670280512","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670280512?lang=zh_cn&edition=full","pubTime":"2026-09-28 16:36","pubTimestamp":1790584569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，健友股份(603707.SH)发布公告，公司子公司香港健友实业有限公司(以下简称“香港健友”)于近日收到美国食品药品监督管理局(以下简称“美国FDA”)签发的维生素B1注射液200mg/2mL(100mg/mL)的ANDA批准通知(ANDA号：213131)。新批准产品进一步丰富了公司国际化的产品管线，强化公司国际市场布局。若后续推进美国市场上市销售，有望对公司经营业绩产生积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0186","LABU","BK4585","BK4588","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409103","title":"股市必读：健友股份新发布《健友股份关于全资子公司参与认购私募基金份额的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409103?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:03","pubTimestamp":1790532193,"startTime":"0","endTime":"0","summary":"公司公告汇总健友股份关于全资子公司参与认购私募基金份额的公告南京健友生化制药股份有限公司全资子公司Emerge Bioscience Pte. Ltd.于2026年9月23日与SouthChina Yitai VCC签署协议，拟以自有资金认购其旗下子基金Whitestream Two的A1类参与份额，出资承诺金额为4,000万美元，初始实缴200万美元。基金期限为首次缴款日起8年，可延长3年，主要投资于生物医药领域。本次投资无需提交公司董事会及股东会审议，不构成关联交易或重大资产重组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0186","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669998734","title":"健友股份（603707）披露全资子公司参与认购私募基金份额公告，9月24日股价下跌2.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669998734","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669998734?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:15","pubTimestamp":1790259355,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，健友股份报收于7.7元，较前一交易日下跌2.65%，最新总市值为124.41亿元。该股当日开盘7.9元，最高7.93元，最低7.69元，成交额达6334.14万元，换手率为0.5%。近日，健友股份发布《关于全资子公司参与认购私募基金份额的公告》。本次投资无需提交公司董事会及股东会审议，不构成关联交易或重大资产重组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400041116.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0046","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669643862","title":"股市必读：健友股份新发布《健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669643862","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669643862?lang=zh_cn&edition=full","pubTime":"2026-09-24 01:20","pubTimestamp":1790184022,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司Meitheal获美国FDA批准硫酸阿米卡星注射液新增南京健友场地生产，ANDA号064045，已投入研发费用约409.08万元。公司公告汇总健友股份关于子公司获得美国FDA硫酸阿米卡星注射液增加生产场地注册批件的公告南京健友生化制药股份有限公司子公司Meitheal Pharmaceuticals Inc.收到美国FDA通知，其申报的硫酸阿米卡星注射液增加生产场地申请获批，批准在南京健友生化制药股份有限公司场地生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400001981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0046","BK0239","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669711242","title":"健友股份：子公司获美国FDA硫酸阿米卡星注射液生产场地批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2669711242","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669711242?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:17","pubTimestamp":1790065020,"startTime":"0","endTime":"0","summary":"9月22日，健友股份(603707.SH)公告称，公司子公司Meitheal Pharmaceuticals Inc.近日收到美国FDA签发的硫酸阿米卡星注射液(500mg/2mL、1g/4mL)增加生产场地的批件，批准在南京健友生化制 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260922/c680169738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4588","LABU","BK0046","BK0186","BK0239","BK4585","603707"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667293476","title":"股市必读：健友股份（603707）9月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2667293476","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667293476?lang=zh_cn&edition=full","pubTime":"2026-09-16 01:09","pubTimestamp":1789492151,"startTime":"0","endTime":"0","summary":"截至2026年9月15日收盘，健友股份报收于7.4元，下跌1.07%，换手率0.24%，成交量3.84万手，成交额2848.68万元。董秘最新回复投资者： 公司现有12条FDA认证的产线，这么多年每次FDA现场核查都顺利通过。当日关注点交易信息汇总：9月15日主力资金净流出80.15万元，占总成交额2.81%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600000786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603707","BK0046","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794111873031,"stockEarnings":[{"period":"1week","weight":0.099},{"period":"1month","weight":0.0842},{"period":"3month","weight":0.0963},{"period":"6month","weight":-0.0117},{"period":"1year","weight":-0.1015},{"period":"ytd","weight":-0.004}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南京健友生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"33838人(较上一季度减少0.51%)","perCapita":"47746股","listingDate":"2017-07-19","address":"江苏省南京市浦口区高新开发区MA010-1号地","registeredCapital":"161565万元","survey":" 南京健友生化制药股份有限公司的主营业务是药物的研发、规模化生产、全球商业化销售并提供一站式无菌注射剂CDMO服务。公司的主要产品是无菌注射剂业务、肝素原料药业务、CDMO业务、生物药创新业务。","listedPrice":7.21},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健友股份,603707,健友股份股票,健友股份股票老虎,健友股份股票老虎国际,健友股份行情,健友股份股票行情,健友股份股价,健友股份股市,健友股份股票价格,健友股份股票交易,健友股份股票购买,健友股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健友股份(603707)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健友股份(603707)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}